AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Company reports unique mechanism of action for cellulite treatment.
2004 SEP 2 - (NewsRx.com & NewsRx.net) -- Enhance Biotech, Inc., (EBOI), a developer of a portfolio of products focused on lifestyle drugs, has reported the discovery of a combination mechanism of action for the company's anticellulite treatment LI303.
The discovery, elucidated in vitro, points to several distinct areas of activity for LI303 which, collectively, influence the behavior of cells critical to the development and establishment of the cellulite condition. The new data helps to explain the molecular basis for the promising cosmetic effects reported in early-stage research, and differentiates the compound from currently available treatments by transiently tightening the surface of the skin.
"Evidence for a new level of activity, which can act to reduce the appearance of cellulite at a structural level, is a major boost for the company's dermatology portfolio and justifies the ...
- Enhance Biotech Engages FDA Approval Advisors Ehrreich Consulting; - Ehrreich...
- Press release article from: PR Newswire February 11, 2004 700+ words
Enhance Biotech Inc. (BULLETIN BOARD: EBOI...approval requirements and procedures. Enhance Biotech pursues a strategy of outsourcing...devices receive FDA approvals. Enhance Biotech currently has seven drugs in Phase...
- Enhance Biotech Engages FDA Approval Advisors Ehrreich Consulting.
- Press release article from: PR Newswire February 11, 2004 700+ words
...PRNewswire/ -- - Ehrreich to support Enhance Biotech as it nears approvals with several of its drugs Enhance Biotech Inc. (OTC Bulletin Board: EBOI...approval requirements and procedures. Enhance Biotech pursues a strategy of outsourcing...
- Enhance Biotech Appoints Acumen Design Associates as Design Development...
- Press release article from: PR Newswire March 16, 2004 700+ words
Enhance Biotech Inc. (BULLETIN BOARD: EBOI...development of delivery methods for Enhance Biotech's male fertility products which...consistently met with commercial success. Enhance Biotech is currently in Phase I and Phase...
- Enhance Biotech Retains Sky Investor Relations.
- Press release article from: PR Newswire January 22, 2004 700+ words
...YORK, January 22 /PRNewswire/ -- Enhance Biotech, Inc. (OTC Bulletin Board: EBOI...Investor Relations. As treatments in Enhance Biotech's portfolio of lifestyle drugs near...Sky IR will increase awareness of Enhance Biotech through investment community introductions...
- Enhance Biotech Inc. Selects Covance to Advance Clinical Research Of Its...
- Press release article from: PR Newswire March 24, 2004 700+ words
Enhance Biotech Inc., (BULLETIN BOARD: EBOI...Phase I clinical trials, LI 313 is Enhance Biotech's family of compounds that address...the market. Chris Every, CEO of Enhance Biotech commented, "Having screened the...
- Enhance Biotech Announces Recruitment of Patients for Dose Ranging Study Prior...
- Press release article from: PR Newswire October 1, 2004 700+ words
Enhance Biotech, Inc. (OTC PK: EBOI), a developer...trial setting." Chris Every, Enhance Biotech's CEO said, "We view LI301 compound...erectile dysfunction market." About Enhance Biotech Enhance Biotech Inc., recently...
- Enhance Biotech Achieves Milestones to Complete $4 Million Funding Arrangement.
- Press release article from: PR Newswire May 20, 2004 700+ words
Enhance Biotech, Inc. (OTC Bulletin Board: EBOI...Under the terms of the arrangement, Enhance Biotech received $2 million in November...arrangement with BioAccelerate. About Enhance Biotech Enhance Biotech Inc. is developing...
- Enhance Biotech Inc. Selects Covance to Advance Clinical Research of its...
- Press release article from: PR Newswire March 24, 2004 700+ words
...YORK, March 24 /PRNewswire/ -- Enhance Biotech Inc., (OTC Bulletin Board: EBOI...Phase I clinical trials, LI 313 is Enhance Biotech's family of compounds that address...the market. Chris Every, CEO of Enhance Biotech commented, "Having screened the...